Navigation Links
Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

REINACH, Switzerland, May 26 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) today announced the enrolment of the first patients into the Phase II "intravenous-to-oral" switch trial with oral iclaprim in complicated Skin and Skin Structure Infections (cSSSI). Enrolment remains on track for completion in 2008.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with a full course of intravenous (i.v.) treatment with vancomycin in the treatment of cSSSI. The primary endpoint will be the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcomes as well as safety and tolerability.

This Phase II trial is designed as a multi-centre, double-blind, double-dummy comparative study. Patients suffering from cSSSI receive i.v. vancomycin for the first two days of treatment and are then randomised to either continue to receive i.v. vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Among the hospital anti-MRSA drugs that are currently in filing or late-stage development, only iclaprim shows oral bioavailability allowing clinical development and consequently offers the potential for intravenous-to-oral switch therapy. We consider the oral switch therapy to be an important option addressing an increasing therapeutic need. It allows patients to be sent home earlier, thereby increasing patient comfort, reducing the risk of contracting additional infections and lowering costs for the healthcare system. We feel the oral switch therapy could add significant potential to the intravenous formulation."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008. The FDA has defined that the Prescription Drug User Fee Act (PDUFA) goal date will be 16 January 2009.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
For further information please contact:


Dr Jurgen Raths, CEO

Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President

Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications

Tel: +41-61-417-96-83

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
Breaking Medicine Technology:
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... It’s ... has a tattoo — a number even greater among Millennials (a whopping one in ... are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
(Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):